[1]刘佳明　潘鹏宇　陈立刚等.紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效[J].中国临床神经外科杂志,2021,26(02):65-67.[doi:10.13798/j.issn.1009-153X.2021.02.001]
　LIU Jia-ming,PAN Peng-yu,CHEN Li-gang,et al.Paclitaxel drug-coated balloon angioplasty for patients with symptomatic vertebral artery origin stenosis[J].,2021,26(02):65-67.[doi:10.13798/j.issn.1009-153X.2021.02.001]
点击复制

紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
26
期数:
2021年02期
页码:
65-67
栏目:
论著
出版日期:
2021-02-25

文章信息/Info

Title:
Paclitaxel drug-coated balloon angioplasty for patients with symptomatic vertebral artery origin stenosis
文章编号:
1009-153X（2021）02-0065-03
作者:
刘佳明　潘鹏宇　陈立刚等
110840 沈阳，中国人民解放军北部战区总医院神经外科（刘佳明、潘鹏宇、陈立刚、赵玉龙、张海峰、董玉书、梁国标、高　旭）
Author(s):
LIU Jia-ming;  PAN Peng-yu;  CHEN Li-gang;  et al
Department of Neurosurgery, General Hospital of Northern Theater Command, PLA, Shenyang 110840, China
关键词:
椎动脉狭窄; 药物涂层球囊; 紫杉醇; 椎动脉开口; 球囊成形术
Keywords:
Vertebral artery origin stenosis;  Drug-coated balloon;  Paclitacxel;  Angioplasty
分类号:
R 743; R 815.2
DOI:
10.13798/j.issn.1009-153X.2021.02.001
文献标志码:
A
摘要:
目的 探讨紫杉醇药物涂层球囊（P-DCB）成形术治疗症状性椎动脉开口狭窄的安全性和有效性。方法 回顾性分析2017 年12月至2019年6月经P-DCB成形术治疗的43例症状性椎动脉开口处狭窄的临床资料。结果 所有病人均完成介入治疗，成功率为100%。术后即刻狭窄率[（12.03±2.15）%]较术前[（86.32±10.26）%]明显降低（P<0.05）。围手术期发生动脉夹层1例，无其他并发症。随访12~16个月，平均13.5个月；症状改善43例，无变化例，症状改善率为95.3%（41/43）；全部病人接受DSA或CTA随访，随访狭窄率[（16.1±3.12）%]与术后即刻无统计学差异（P>0.05）；5例发生再狭窄，再狭窄率为11.6%。结论 P-DCB成形术治疗椎动脉开口狭窄具有较好的临床疗效。
Abstract:
Objective To evaluate the efficacy and safety of paclitacxel drug-coated balloon (P-DCB) angioplasty for the patients with symptomatic vertebral artery origin stenosis (VARS). Methods The clinical data of 43 consecutive patients with symptomatic VARS who underwent P-DCB angioplasty from December 2017 to June 2019 were analyzed retrospectively. Results All the procedures were completed successfully, and the success rate was 100%. The immediate postoperative stenosis rate [(12.03±2.15)%] was significantly lower than that [(86.32±10.26)%] before the operation (P<0.05). Arterial dissection occurred in 1 patient during the perioperative period. The follow-up ranged from 12 months to 16 months, with an average of 13.5 months. The symptomatic improvement rate was 95.3% (41/43). There was no statistical difference between the follow-up stenosis rate [(16.1±3.12 )%] and the immediate postoperative stenosis rate (P>0.05). Restenosis occurred in 5 patients and the restenosis rate was 11.6% (5/43). Conclusion P-DCB angioplasty is a safe and good method for treatment of the patients with symptomatic VARS.

参考文献/References:

[1] Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1, 000 consecutive patients with first stroke [J]. Stroke, 1988, 19(9): 1083-1092.
[2] Bamoford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction [J]. Lancet, 1991, 337(8756): l521-1526.
[3] Caplan LR, Amarenco P, Rosengart A, et al. Embolism from vertebral artery origin occlusive disease [J]. Neurology, 1992, 42(8): 1505.
[4] Ko JK, Choi CH, Hwangbo L, et al. Endovascular treatment of the vertebral artery origin stenosis by using the closed-cell, self-expandable Carotid Wallstent [J]. Interv Neurora-diol, 2020, 26(6): 805-813.
[5] Thompson MC, Issa MA, Lazzaro MA, et al. The natural history of vertebral artery origin stenosis [J]. J Stroke Cere-brovasc Dis, 2014, 23(1): 1-4.
[6] Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysisof randomised clinical trials [J]. Lancet, 2019, 393(10190): 2503-2510.
[7] Vajda Z, Miloslavski E, Güthe T, et al. Treatment of stenosesof vertebral artery origin using short drug-eluting coronary stents: improved follow-up results [J]. AJNR Am J Neurora-diol, 2009, 30(9): 1653-1656.
[8] Zhu Y, Hu G, Ke X, et al. Comparison of the efficacy of drug-eluting balloon for de novo lesions and in-stent res-tenosis lesions of the femoropopliteal arteries [J]. Laparo-scopic, Endoscopic Robotic Surg, 2019, 2(3): 59-64.
[9] North American symptomatic carotid endarterectomy trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis [J]. NEngl J Med, 1991, 325(7): 445-453.
[10] Malek AM, Higashida RT, Phatouros CC, et al. Treatment of posterior circulation ischemia with extracranial percuta-neous balloon angioplasty and stent placement [J]. Stroke, 1999, 30(10): 2073-2085.
[11] 吴　丹. 药物洗脱球囊在冠脉介入治疗后支架内再狭窄病变中的应用进展[J]. 中国医疗器械信息，2019，25（14）：15-16.
[12] Ahmed, Kayssi, Wissam, et al. Drug-eluting balloon angio-plasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries [J]. Cochrane Database Syst Rev, 2019, 1(1): CD012510.

相似文献/References:

[1]魏　恒　马江红　张　华　曹　敏　徐丽琴　曾静霞.Wingspan支架置入术治疗椎动脉狭窄的疗效观察[J].中国临床神经外科杂志,2015,(07):430.[doi:10.13798/j.issn.1009-153X.2015.07.017]
[2]燕景锋　樊立华　任崇文　贾增强　何金超　孙　鹏.单一支架置入术治疗椎-锁骨下动脉联合狭窄[J].中国临床神经外科杂志,2017,(05):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
　YAN Jing-feng,FAN Li-hua,REN Chong-wen,et al.Outcomes of single stent technique in subclavian-vertebral artery bifurcation series stenoses[J].,2017,(02):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
[3]王晓莉,张维文,张方圆,等.氯吡格雷抵抗对椎动脉狭窄支架术后再狭窄的影响[J].中国临床神经外科杂志,2022,27(07):585.[doi:10.13798/j.issn.1009-153X.2022.07.019]

备注/Memo

备注/Memo:
基金项目：国家重点研发计划项目（2016YFC1301703）
通讯作者：高　旭，E-mail：gaoelmer@hotmail.com
更新日期/Last Update: 2021-02-25